Biosimilar switching evidence dossier: immunogenicity and efficacy data summary for 6 market access submissions
Switching evidence needs to be both robust and locally relevant
For a biosimilar entering six markets, the critical access question was not bioequivalence — that had been established. The question was switching: could patients already stable on the reference product be safely transitioned to the biosimilar without loss of efficacy or increased immunogenicity risk?
The switching evidence base was genuinely strong — multiple real-world studies from national registries and observational cohorts. But the studies used different endpoints, different follow-up periods, and different definitions of 'adverse switching event'. Individually, each study was credible. Collectively, they were difficult to present coherently to a payer body expecting a structured dossier.
Six tender submissions were approaching, each with different format requirements and different levels of sophistication from the reviewing body. A single unsupported document would not serve all six markets.
For biosimilars, the switching evidence is often more important for access than the bioequivalence data. It needs to be synthesised, structured, and market-adapted to do its access work.
What we did
Measurable impact
The consolidated switching evidence dossier was used across all 6 tender submissions. The biosimilar was added to formulary in all 6 markets. Market Access teams in two markets specifically credited the quality of the immunogenicity synthesis as differentiating the submission from competitor biosimilar applications for the same reference product.
across all markets
evidence synthesis
achieved
Tell us what you’re working on — we’ll show you relevant cases and suggest the fastest path forward.
From the field:
evidence & practice
AI-powered.
Expert-validated.
We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.